Oruka Therapeutics, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Lawrence Klein (President/CEO) and Arjun Agarwal (SVP Finance/Treasurer) certified the Form 10-Q for the quarter ending June 30, 2026, filed August 10, 2026. Both officers certified under SOX 302 and 906 that financial statements fairly present the company's condition, operations, and cash flows; that disclosure and internal controls are effective; and that no material misstatements or fraud was identified. No specific operational, financial, or control deficiencies were disclosed in these exhibits.
Why this rating
Routine SOX certification exhibits; standard periodic disclosure. No substantive events, transactions, or control issues disclosed relative to $371.5M market cap.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.